LODINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LODINE (LODINE).
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
| Metabolism | Primarily hepatic via CYP2C9; undergoes conjugation; multiple metabolites including 6-hydroxyetodolac. |
| Excretion | Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%) |
| Half-life | Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment |
| Protein binding | >99% bound, primarily to albumin |
| Volume of Distribution | Approximately 0.4 L/kg (range 0.3-0.5 L/kg), indicating distribution into total body water |
| Bioavailability | Oral: ~80% with extensive first-pass metabolism; absolute bioavailability not defined due to lack of IV formulation |
| Onset of Action | Oral: analgesic effect within 30-60 minutes; anti-inflammatory effect within 1-2 weeks of continuous dosing |
| Duration of Action | Analgesic duration 4-6 hours; anti-inflammatory effect sustained with regular dosing |
| Molecular Weight | 311.35 |
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment needed; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A or B: use with caution, consider reducing dose by 50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Not established for children under 18 years; safety and efficacy not determined. |
| Geriatric use | Initiate at lowest effective dose (e.g., 200 mg every 8-12 hours); maximum daily dose 400 mg; monitor renal function and GI bleeding risk. |
| 1st trimester | Avoid use; associated with oligohydramnios, premature closure of ductus arteriosus, and fetal renal impairment. NSAIDs are generally avoided in first trimester due to potential increased risk of miscarriage. |
| 2nd trimester | Avoid use; may cause oligohydramnios, premature ductus arteriosus constriction, and fetal nephrotoxicity. |
| 3rd trimester | Avoid use in third trimester; risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for LODINE (LODINE).
| Placental transfer | Crosses placenta; detectable in fetal plasma and amniotic fluid. |
| Breastfeeding | Excreted into breast milk in low amounts; consider risk of kernicterus in neonates with hyperbilirubinemia. Use with caution, especially in preterm infants or those with compromised renal function. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk.
| Serious Effects |
Hypersensitivity to etodolac or other NSAIDsHistory of asthma, urticaria, or allergic-type reactions after intake of aspirin or other NSAIDsActive peptic ulcer disease or gastrointestinal bleedingSevere heart failure (NYHA Class IV)Coronary artery bypass graft (CABG) surgery perioperative painThird trimester of pregnancy
| Precautions | Cardiovascular thrombotic events (MI, stroke), especially with prolonged use or pre-existing cardiovascular disease; GI toxicity; hypertension; fluid retention; renal toxicity; hepatic dysfunction; anaphylactoid reactions; serious skin reactions; asthma exacerbation; hematologic effects; use in late pregnancy should be avoided. |
| Food/Dietary | Avoid alcohol as it increases risk of GI bleeding. High-fat meals may delay absorption but do not affect overall exposure. No specific food restrictions. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C: Avoid during first and second trimester unless clearly needed; may cause premature closure of ductus arteriosus and oligohydramnios in third trimester. |
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of bleeding; fetal ultrasound for oligohydramnios and ductus arteriosus patency if used in third trimester. |
| Fertility Effects | May impair female fertility via inhibition of prostaglandin synthesis affecting ovulation; reversible upon discontinuation. |
| Clinical Pearls | LODINE (etodolac) is an NSAID with preferential COX-2 inhibition, reducing GI toxicity relative to non-selective NSAIDs. It is indicated for acute pain and osteoarthritis. Onset of analgesia is within 30 minutes. Use with caution in patients with renal impairment, hypertension, or heart failure. Avoid in perioperative pain of CABG surgery. Monitor renal function, blood pressure, and signs of GI bleeding in chronic use. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin unless directed. · Report signs of GI bleeding: black/tarry stools, vomit that looks like coffee grounds. · Avoid alcohol while taking this medication. · Notify your doctor if you develop swelling, weight gain, or shortness of breath. · Use lowest effective dose for shortest duration. |